KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Non-Current ReceivablesReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Novartis Ag (NVS) Non-Current Receivables (2017 - 2025)

Novartis Ag's Non-Current Receivables history spans 7 years, with the latest figure at $179.0 million for Q4 2024.

  • For Q4 2024, Non-Current Receivables fell 16.36% year-over-year to $179.0 million; the TTM value through Dec 2024 reached $179.0 million, down 16.36%, while the annual FY2024 figure was $179.0 million, 16.36% down from the prior year.
  • Non-Current Receivables for Q4 2024 was $179.0 million at Novartis Ag, down from $214.0 million in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $214.0 million in Q4 2023 and bottomed at $125.0 million in Q4 2020.
  • The 5-year median for Non-Current Receivables is $184.0 million (2021), against an average of $179.8 million.
  • The largest annual shift saw Non-Current Receivables surged 47.2% in 2021 before it fell 16.36% in 2024.
  • A 5-year view of Non-Current Receivables shows it stood at $125.0 million in 2020, then soared by 47.2% to $184.0 million in 2021, then grew by 7.07% to $197.0 million in 2022, then increased by 8.63% to $214.0 million in 2023, then decreased by 16.36% to $179.0 million in 2024.
  • Per Business Quant, the three most recent readings for NVS's Non-Current Receivables are $179.0 million (Q4 2024), $214.0 million (Q4 2023), and $197.0 million (Q4 2022).